Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRANASDAQ:CNCEOTCMKTS:CXRXFNASDAQ:HOOKNASDAQ:MEIP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRABiofrontera$2.60$2.95$2.09▼$7.54$73.73M1.0227,512 shs7,263 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/ACXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsHOOKHOOKIPA Pharma$1.18-4.1%$1.40$0.72▼$6.77$14.99M0.8982,750 shs52,068 shsMEIPMEI Pharma$2.62-2.2%$2.24$1.46▼$4.10N/A0.1944,324 shs14,596 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRABiofrontera0.00%0.00%0.00%0.00%0.00%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%HOOKHOOKIPA Pharma0.00%+1.20%-18.91%+55.04%-77.61%MEIPMEI Pharma0.00%+1.25%+30.05%+46.89%+1.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRABiofronteraN/AN/AN/AN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AN/AN/AN/AHOOKHOOKIPA Pharma2.9359 of 5 stars3.25.00.00.00.01.70.6MEIPMEI Pharma2.5158 of 5 stars0.05.00.04.20.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRABiofrontera 0.00N/AN/AN/ACNCEConcert Pharmaceuticals 0.00N/AN/AN/ACXRXFADVANZ PHARMA 0.00N/AN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50281.36% UpsideMEIPMEI Pharma 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRABiofrontera$36.19M2.04N/AN/A$0.35 per share7.43CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58CXRXFADVANZ PHARMA$525.58M1.59N/AN/A$0.16 per share106.63HOOKHOOKIPA Pharma$43.95M0.33N/AN/A$4.25 per share0.28MEIPMEI Pharma$65.30MN/A$5.82 per share0.45$4.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRABiofrontera-$14.88M-$0.73N/A∞N/A-59.44%-93.31%-24.02%N/ACNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/ACXRXFADVANZ PHARMA-$74.86MN/AN/A∞N/A-15.31%N/A-4.38%N/AHOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/17/2025 (Estimated)Latest CNCE, CXRXF, BFRA, HOOK, and MEIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRABiofronteraN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRABiofrontera0.131.261.13CNCEConcert PharmaceuticalsN/A9.039.03CXRXFADVANZ PHARMA257.042.391.61HOOKHOOKIPA PharmaN/A3.613.61MEIPMEI PharmaN/A16.7816.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRABiofrontera60.07%CNCEConcert Pharmaceuticals70.63%CXRXFADVANZ PHARMAN/AHOOKHOOKIPA Pharma63.88%MEIPMEI Pharma52.38%Insider OwnershipCompanyInsider OwnershipBFRABiofronteraN/ACNCEConcert Pharmaceuticals11.33%CXRXFADVANZ PHARMAN/AHOOKHOOKIPA Pharma3.30%MEIPMEI Pharma3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRABiofrontera13828.36 millionN/ANot OptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableCXRXFADVANZ PHARMA42948.91 millionN/ANot OptionableHOOKHOOKIPA Pharma5612.19 million11.79 millionOptionableMEIPMEI Pharma100N/AN/AOptionableCNCE, CXRXF, BFRA, HOOK, and MEIP HeadlinesRecent News About These CompaniesMEI Pharma, Inc. (MEIP) Stock Price, Quote, News & Analysis - Seeking AlphaJune 26, 2025 | seekingalpha.comMEI Pharma Reports Third Quarter Fiscal Year 2025 Cash PositionMay 13, 2025 | businesswire.comMEI Pharma Reports Second Quarter Fiscal Year 2025 Cash PositionFebruary 12, 2025 | finance.yahoo.comMEI Pharma Registered ShsJanuary 22, 2025 | markets.businessinsider.comMEI Pharma (NASDAQ:MEIP) Stock, Option ChainNovember 18, 2024 | benzinga.comMEI Pharma Reports First Quarter Fiscal Year 2025 Cash PositionNovember 13, 2024 | finance.yahoo.comWhat’s Fueling MEI Pharma Inc (MEIP) Stock’s -20.38% Loss Below Its 200-Day SMA?October 27, 2024 | bovnews.comBMEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 MillionOctober 25, 2024 | marketwatch.comMEI Pharma gets grant for compounds for treating proliferative diseasesSeptember 24, 2024 | pharmaceutical-technology.comPTelix Pharmaceuticals Limited (T3X.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comMEI Pharma reviews strategic options amid fiscal changesSeptember 21, 2024 | investing.comMEI Pharma Reports Fiscal Year End 2024 Cash PositionSeptember 19, 2024 | finance.yahoo.comMEI Pharma Reports Fiscal Year End 2024 Cash PositionSeptember 19, 2024 | businesswire.comMEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic AlternativesAugust 12, 2024 | finance.yahoo.comLaidlaw & Co. Downgrades MEI Pharma (MEIP)July 24, 2024 | msn.comMEI Pharma Considering Strategic Alternatives; CEO Urso Steps DownJuly 22, 2024 | marketwatch.comMEI Pharma, after failed Infinity merger last year, to evaluate strategic alternativesJuly 22, 2024 | fiercebiotech.comFMEI Pharma To Begin Evaluation Of Strategic Alternatives - Quick FactsJuly 22, 2024 | markets.businessinsider.comMEI Pharma to Consider Strategic AlternativesJuly 22, 2024 | businesswire.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsJuly 1, 2024 | investorplace.comMedia Sentiment Over TimeCNCE, CXRXF, BFRA, HOOK, and MEIP Company DescriptionsBiofrontera NASDAQ:BFRABiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Concert Pharmaceuticals NASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.ADVANZ PHARMA OTCMKTS:CXRXF$17.06 0.00 (0.00%) As of 06/10/2021ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.HOOKIPA Pharma NASDAQ:HOOK$1.18 -0.05 (-4.07%) As of 04:00 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.MEI Pharma NASDAQ:MEIP$2.62 -0.06 (-2.24%) Closing price 04:00 PM EasternExtended Trading$2.65 +0.03 (+1.15%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
